TrialClinical and translational medicine2023

A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.

Barbara Klughammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.